- Home
- UHS vs BMRN Comparison
UHS vs BMRN Comparison
Compare UHS & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHS
- BMRN
- Stock Information
- Founded
- UHS 1978
- BMRN 1996
- Country
- UHS United States
- BMRN United States
- Employees
- UHS N/A
- BMRN N/A
- Industry
- UHS Hospital/Nursing Management
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- UHS Health Care
- BMRN Health Care
- Exchange
- UHS Nasdaq
- BMRN Nasdaq
- Market Cap
- UHS 11.7B
- BMRN 12.1B
- IPO Year
- UHS N/A
- BMRN 1999
- Fundamental
- Price
- UHS $181.75
- BMRN $58.86
- Analyst Decision
- UHS Buy
- BMRN Buy
- Analyst Count
- UHS 17
- BMRN 22
- Target Price
- UHS $222.31
- BMRN $93.43
- AVG Volume (30 Days)
- UHS 846.0K
- BMRN 1.6M
- Earning Date
- UHS 04-28-2025
- BMRN 05-01-2025
- Dividend Yield
- UHS 0.44%
- BMRN N/A
- EPS Growth
- UHS 51.30
- BMRN 152.82
- EPS
- UHS 17.80
- BMRN 2.71
- Revenue
- UHS $16,084,073,000.00
- BMRN $2,950,227,000.00
- Revenue This Year
- UHS $9.55
- BMRN $12.27
- Revenue Next Year
- UHS $5.42
- BMRN $9.86
- P/E Ratio
- UHS $10.22
- BMRN $21.79
- Revenue Growth
- UHS 9.73
- BMRN 19.36
- 52 Week Low
- UHS $153.99
- BMRN $52.93
- 52 Week High
- UHS $243.25
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- UHS 54.48
- BMRN 37.63
- Support Level
- UHS $175.41
- BMRN $58.74
- Resistance Level
- UHS $187.98
- BMRN $61.26
- Average True Range (ATR)
- UHS 5.90
- BMRN 1.98
- MACD
- UHS 1.58
- BMRN -0.03
- Stochastic Oscillator
- UHS 79.49
- BMRN 1.80
About UHS Universal Health Services Inc.
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two segments: Acute Care Hospital Services and Behavioral Health Services. The company generates the majority of its revenue from the Acute Care Hospital Services segment. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.